Meet Shimon Sakaguchi, Winner Nobel 2025 in Medicine

Scientists won the Nobel Prize
12 followers
2 Video Views·Sep 25, 2026
AI Generated·May contain errors
Video Summary
AI GeneratedDr. Shimon Sakaguchi, Mary E. Brunkow, and Fred Ramsdell were awarded the Nobel Prize in Physiology or Medicine for discovering peripheral immune tolerance. Their work identified regulatory T-cells (Tregs) and the FOXP3 gene, solving the paradox of how the immune system protects the body without attacking its own healthy tissues.
On a cool October morning in 2025, the phone rang in a laboratory at Osaka University.
At 74, Dr. Shimon Sakaguchi, a man known for his quiet modesty and intense focus,
was back from a conference and in his office. The call was from Stockholm. On the line,
Thomas Perlman, the Secretary General of the Nobel Committee for Physiology or Medicine,
delivered the news that caps a scientific lifetime.
Dr. Sakaguchi, along with two American scientists, Mary E. Brunkow
and Fred Ramsdell, had been awarded the Nobel Prize in Physiology or Medicine.
The recognition was for their discoveries concerning peripheral immune tolerance,
a phrase that belies the profound biological paradox they had solved.
Sakaguchi's reaction was one of gratitude, and what he later called a pleasant surprise.
The human immune system is the body's powerful army, a complex network of cells and organs that
wages a constant, silent war against invaders like bacteria and viruses. Without it, we would
not survive. Yet, this same army possesses the terrifying capacity to turn on its own country,
to mistake healthy tissue for a foreign enemy and launch a devastating attack.
This friendly fire is the basis of autoimmune diseases like type 1 diabetes,
rheumatoid arthritis, and multiple sclerosis. For decades, immunologists grappled with a
How does this army know when to stop fighting? How does it maintain peace within the body
it is sworn to protect? The answer required a persistent immunologist from Japan over a decade
to challenge a deeply entrenched dogma, to swim against the tide of scientific consensus,
and to resurrect a field of study that his peers had left for dead.
This is the story of how Shimon Sakaguchi discovered the immune system's peacekeepers.
To understand Sakaguchi's achievement, one must first understand the army he sought to command.
The immune system has two main branches. The first is the innate system, a set of general
defenses like skin and reflexes that act as the body's first line of patrol. The second is the
adaptive system, an elite special forces unit that learns, remembers, and mounts highly specific
attacks against particular enemies. The star soldiers of this adaptive army are white blood
cells called T-cells. Born in the bone marrow, these cells mature in an organ called the thymus,
a small gland located behind the breastbone. Here, in this biological boot camp, they are trained to
In the 1980s, the prevailing scientific consensus held that this training process,
known as central tolerance, was the primary, if not sole, mechanism for preventing autoimmunity.
The theory was simple and elegant. As T-cells mature in the thymus, they are tested. Any T-cell
that shows the potential to attack the body's own proteins is ordered to commit suicide,
a process called negative selection. Only the soldiers that pass this loyalty test are allowed
to graduate and patrol the body. Faulty soldiers were simply destroyed before they could be deployed.
Yet this explanation had holes. Some self-reactive T-cells were known to escape the thymus and enter
circulation. What stopped them from wreaking havoc? In the 1970s, some researchers had proposed the
existence of suppressor T-cells, a hypothetical police force that could rein in rogue immune
responses. But the field was plagued by inconsistent experiments and a lack of specific molecular
markers. When a key piece of genetic evidence for these cells, a region of DNA called the IJ locus,
was proven not to exist, the theory collapsed spectacularly. By the mid-1980s, the study of
suppressor T-cells was not just unpopular, it was a professional embarrassment. Cellular immunology
was dismissed by the rising molecular biologists. Nobody believed in these cells anymore.
It was into this scientific wasteland that Shimon Sakaguchi chose to venture.
He was not simply filling a gap in the scientific literature. He was challenging the collective
judgment of his peers that the gap was a dead end. The man who would challenge this dogma was
shaped by a world of quiet intellectualism. Shimon Sakaguchi was born in 1951 in Shiga Prefecture,
a peaceful region near Japan's Lake Biwa. His upbringing was steeped in learning. His father,
a high school principal with a degree in western philosophy, named his son Shimon from the Bible.
His mother's family had a long lineage of doctors, stretching back to the Edo period.
This household that valued learning fostered what one account calls an inquisitive boy,
who loved science experiments and reading from a young age. Following in his mother's family
tradition, he entered the prestigious Kyoto University to study medicine. He initially
planned to become a clinical doctor, a practical profession where one could have a skill. But during
his studies, he became captivated by a deeper question. He was, as he later recalled, intrigued
by the paradoxical nature of the immune system. He felt that, if he could resolve this paradox,
a universal principle behind autoimmune disease would be revealed.
This philosophical quest led him to make a pivotal decision. He chose the uncertain path of basic
research over the clear-cut duties of a physician, even dropping out of his graduate program to
devote himself to research at the Aichi Cancer Center. It was there that he encountered the
experiment that would define his career. To be a lone voice in science is a difficult path.
In the 1980s, as Sakaguchi began his quest, the field of suppressor T-cells was in ruins.
He was one of the lone scientists still willing to support the theory of active suppression.
The work was unpopular, and he later admitted that he had to struggle at times to earn research
funding. The scientific challenge was a huge one. If these regulatory T-cells were real,
they looked exactly like the millions of other T-cells floating around in the bloodstream.
Finding them was like trying to pick out a specific grain of sand on a giant beach.
The only way to get them out was to find a special molecular marker, a protein on their surface that
wasn't on other T-cells. This hunt for the marker became his main focus.
We tried so many markers to pick out cell populations, he said, which really doesn't
do justice to years of super-detailed, often frustrating, lab work. The struggle lasted
for more than a decade. Finally, in 1995, he had his breakthrough. In a landmark paper
published in the Journal of Immunology, Sakaguchi announced that he had found them.
He had identified a small subset of T-cells that carried not only the standard CD4 protein
of helper T-cells, but also another surface protein called CD25. When he removed these
cells from mice, they developed autoimmune diseases. When he injected them back,
the diseases were prevented. He had found the immune system's peacekeepers.
He named them regulatory T-cells, or T-Rex. But not everyone was immediately on board.
The earlier suppressor T-cell mess still lingered in people's minds. As the Nobel Committee put it,
many researchers were skeptical about its existence. They wanted more proof.
Sakaguchi had found the cell, but he hadn't yet figured out the basic genetic controls behind it.
We knew what it was, but how and why it worked was still a big question mark.
The final pieces of the puzzle would come not from Japan, but from a biotech company
in Bothell, Washington. There, two American scientists, Mary Brunkow and Fred Ramsdell,
were engrossed in a strange strain of laboratory mice known as scurvy mice.
These animals were born with a genetic defect that caused their immune systems to run amok,
leading to severe skin problems, massively enlarged spleens, and early death.
Brunkow and Ramsdell realized that if they could find the single broken gene responsible
for this chaos, it could provide important clues into human autoimmune diseases.
Their quest was a needle in a haystack search through the mouse genome.
They narrowed the location of the mutation to a stretch of the X-chromosome containing about 20
genes. Then, with painstaking effort, they compared each gene one by one between healthy
and scurvy mice. In 2001, in the 20th and final gene, they found it. A mutation in a previously
unknown gene they named FOXP3. In a crucial extension of their work, they showed that
mutations in the human version of this same gene caused IPEX, a rare but devastating autoimmune
syndrome in young boys. They had found the genetic master key to immune regulation,
though they did not yet know precisely which door it unlocked.
It was Shimon Sakaguchi who saw the connection. Two years after Brunkow and Ramsdell's discovery,
he published the Grand Synthesis. He proved that the FOXP3 gene was nothing less than the
master control gene for the regulatory T-cells he had discovered eight years earlier. When his
lab artificially put the FOXP3 gene into regular T-cells, it basically turned them into the
peacekeeping Treg cells. So these two different research paths, one looking at cells and how they
function in Japan, and the other focusing on molecules and genetics in the US, had basically
landed on the same big truth. Sakaguchi's cells now had a clear genetic reason for being what
they were, which shut up the doubters and Brunkow and Ramsdell's gene now had a clear job in the
cells. The discovery was complete and a whole new area of immunology was born. The identification
of Tregs in their master gene, FOXP3, opened a new frontier in medicine. It provided a tangible
target for treating a vast array of human diseases by learning to manipulate the body's
own peacekeepers. Clinical trials are now underway exploring this potential.
The applications are threefold. For autoimmune diseases like lupus and type 1 diabetes,
where the immune army is too aggressive, the goal is to boost Treg numbers or enhance their function,
calming the attack. Therapies involving the adoptive transfer of a patient's own Tregs,
grown and expanded in the lab, are being tested. A similar approach could help the body accept
transplanted organs, preventing rejection. The application to cancer is brilliantly paradoxical.
Scientists have found that tumors can be pretty sneaky. They can actually trick Tregs into
creating a protective bubble around them, basically telling the immune system's soldiers
to chill out. So, the treatment plan here is to do the opposite, block or get rid of those Tregs
near the tumor. That way we can take the brakes off and let the immune system see and destroy the
cancer cells. For Sakaguchi, seeing his life's work actually help people in the clinic is the
ultimate reward. He's often talked about wanting to use our basic research to treat and prevent
diseases that affect so many people. When he got the Nobel, he even said he hoped for more progress,
so these discoveries would lead to prevention of diseases. That's what our research is for.
He pictures a future where even cancer will be no longer scary but treatable.
